- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT05006404
Autus Valve vroege haalbaarheidsstudie
Autus in grootte verstelbare klep voor chirurgische vervanging van de longklep Vroege haalbaarheidsstudie
Prospective, single-arm, multi-center study to evaluate safety and effectiveness of the Autus Size-Adjustable Valve in pediatric patients aged 18 months to 16 years requiring surgical pulmonary valve replacement. The Autus Valve may be expanded pre-implant to match the subject's body size. Subjects will be evaluated prior to the Autus Valve implant procedure, immediately post-implant, at hospital discharge, 30 days, 6 months, and annually through 10 years.
The Autus Valve may be expanded post-implant via transcatheter balloon dilation to accommodate growth of the subject. In subjects who undergo a post-implant valve expansion, follow-up will continue for a minimum of 1 year after the post-implant valve expansion procedure.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Studietype
Inschrijving (Werkelijk)
Fase
- Niet toepasbaar
Contacten en locaties
Studie Locaties
-
-
California
-
Los Angeles, California, Verenigde Staten, 90027
- Children's Hospital Los Angeles
-
-
Colorado
-
Aurora, Colorado, Verenigde Staten, 80045
- Children's Hospital Colorado
-
-
Georgia
-
Atlanta, Georgia, Verenigde Staten, 30322
- Children's Healthcare of Atlanta
-
-
Illinois
-
Chicago, Illinois, Verenigde Staten, 60611
- Ann and Robert H. Lurie Children's Hospital of Chicago
-
-
Massachusetts
-
Boston, Massachusetts, Verenigde Staten, 02115
- Boston Children's Hospital
-
-
Michigan
-
Ann Arbor, Michigan, Verenigde Staten, 48109
- University of Michigan - Mott Children's Hospital
-
-
New York
-
New York, New York, Verenigde Staten, 10032
- Columbia University Irving Medical Center/New York Presbyterian Morgan Stanley Children's Hospital
-
-
North Carolina
-
Durham, North Carolina, Verenigde Staten, 27703
- Duke University
-
-
Ohio
-
Columbus, Ohio, Verenigde Staten, 43205
- Nationwide Children's Hospital
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Verenigde Staten, 19104
- Children's Hospital of Philadelphia
-
-
Utah
-
Salt Lake City, Utah, Verenigde Staten, 84113
- University of Utah - Intermountain Primary Children's Hospital
-
-
Washington
-
Seattle, Washington, Verenigde Staten, 98105
- Seattle Children's Hospital
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
Candidates must meet all of the following inclusion criteria to be considered for enrollment in this study.
-
Age 18 months to 16 years.
-
Male or female.
-
Subject has a native or repaired right ventricular outflow tract.
-
Subject has been recommended for surgical pulmonary valve replacement by treating clinical team (cardiologist and cardiac surgeon).
-
Subject has at least one of the following echocardiographic findings:
- Severe pulmonary stenosis (defined as RV to PA peak instantaneous gradient ≥60 mmHg);
- Moderate or greater pulmonary regurgitation;
- Moderate or greater pulmonary stenosis plus moderate or greater pulmonary regurgitation.
-
Subject's body size is suitable for implantation of a study device ranging from 12.7 to 22 mm (internal diameter).
-
Subject and parent/legal representative, where appropriate, are willing to provide informed written consent.
-
Subject and parent/legal representative, where appropriate, and treating physician agree that the subject will return for, and comply with, all required study assessments and follow-up visits.
Exclusion Criteria:
Candidates will be excluded from the study if any of the following conditions are met:
- Subject requires valve replacement in a non-pulmonary position.
- Subject has a prosthetic valve at other valve position or will need a prosthetic valve at other valve position (i.e., anticipate additional valve replacements needed within 3 years).
- Subject has pulmonary arterial hypertension (defined as mean PA pressure ≥25 mmHg).
- Subject has pulmonary atresia and major aortopulmonary collaterals.
- Subject has significant peripheral pulmonary artery stenosis.
- Subject has an active infection requiring current systemic antibiotic therapy (if temporary illness, subject may be a candidate 4 weeks after discontinuation of antibiotics).
- Subject has active endocarditis or a history of infective endocarditis.
- Subject has renal insufficiency as determined by a serum creatinine (S-Cr) level ≥2.5 mg/dL within 60 days prior to the Screening Visit, or has end-stage renal disease.
- Subject has leukopenia (defined as a white blood cell (WBC) count <3.5 x 103/µL)
- Subject has acute or chronic anemia (defined as hemoglobin (Hgb) <10.0 g/dl or 6 mmol/L).
- Subject has thrombocytopenia (defined as platelet count <50 x 103/µL.
- Subject has a known hypersensitivity to anticoagulants and antiplatelet drugs.
- Subject has a known autoimmune disease or receives immunosuppressant and/or immunostimulant drugs that the Investigator or Eligibility Screening Committee (ESC) believes may negatively affect study outcomes.
- Subject needs emergency cardiac or vascular surgery or intervention.
- Positive pregnancy test prior to valve implant procedure in female subjects who have had their first menses.
- Subject has, in the opinion of the Investigator, a life expectancy of less than 5 years.
- Subject or parent/legal representative refuses blood transfusions.
- Subject has medical, social or psychosocial factors that, in the opinion of the Investigator or ESC, could impact safety or compliance with study procedures.
- Subject is participating in an investigational study of a new drug, biologic or device at the time of study screening.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: NVT
- Interventioneel model: Opdracht voor een enkele groep
- Masker: Geen (open label)
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Experimenteel: Autus Valve Arm
Pulmonary Valve Replacement Surgery with the Autus Valve |
Pulmonary valve replacement surgery with the Autus Valve |
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Valve Implantation Primary Safety Endpoint
Tijdsspanne: 30 Days post-valve implantation
|
Composite Endpoint: Freedom from a device-related complication through 30 days post-valve implantation as adjudicated by an independent Clinical Events Committee (CEC), including:
|
30 Days post-valve implantation
|
|
Valve Implantation Primary Effectiveness Endpoint
Tijdsspanne: 6 Months post-valve implantation
|
Acceptable hemodynamic performance at 6 months post-valve implantation, as assessed by the Echocardiography Core Laboratory or Clinical Events Committee, defined as:
|
6 Months post-valve implantation
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Other Safety Outcome - Composite
Tijdsspanne: 6 months and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
The following other safety outcome will be evaluated at 6 months, and annually through 10 years post-valve implantation by an independent Clinical Events Committee. The composite outcome includes device-related:
|
6 months and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
|
Other Safety Outcome - Mortality
Tijdsspanne: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year. • Mortality, including: all cause, cardiac-related, procedure-related and device-related |
30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
|
Other Safety Outcome - Valve Thrombosis
Tijdsspanne: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year. • Valve thrombosis |
30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
|
Other Safety Outcome - Thromboembolism
Tijdsspanne: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year. • Thromboembolism |
30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
|
Other Safety Outcome - Cardiac or Valve Intervention
Tijdsspanne: 30 days, 6 months, and annually through a minimum of 510 years and up to 11 years post-valve implantation
|
The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year. • Other cardiac or valve intervention (surgical or transcatheter) |
30 days, 6 months, and annually through a minimum of 510 years and up to 11 years post-valve implantation
|
|
Other Safety Outcome - Major Hemorrhage
Tijdsspanne: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year. • Major hemorrhage |
30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
|
Other Safety Outcome - Endocarditis
Tijdsspanne: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year. • Endocarditis |
30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
|
Other Safety Outcome - Hemolysis
Tijdsspanne: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year. • Hemolysis |
30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
|
Other Safety Outcome - Device Explantation
Tijdsspanne: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
The following measure will be evaluated by an independent Clinical Events Committee at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year. • Device explantation |
30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
|
Other Safety Outcome - Adverse Events (AE)
Tijdsspanne: 30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
The following measure will be reported at 30 days, 6 months, and annually through 10 years post-valve implantation. Subjects that undergo valve expansion in year 10 after device implantation will be followed for an additional year. • Adverse events |
30 days, 6 months, and annually through a minimum of 10 years and up to 11 years post-valve implantation
|
|
Other Safety Outcome - Valve/Stent Fracture
Tijdsspanne: pre-discharge, 12 months, and annually through a minimum of 5 years and up to 6 years post-valve implantation. Subjects that undergo post-implant valve expansion will be evaluated pre-discharge and at 12 months post-valve expansion.
|
An independent Medical Reviewer will review post-implant chest x-rays to assess for valve/stent fracture. Chest x-rays will be performed at the following timepoints: post-valve implantation at hospital discharge, and annually through 5 years post-valve implantation. If a post-implant valve expansion procedure is performed, chest x-rays will be performed at hospital discharge and 12 months post-procedure. |
pre-discharge, 12 months, and annually through a minimum of 5 years and up to 6 years post-valve implantation. Subjects that undergo post-implant valve expansion will be evaluated pre-discharge and at 12 months post-valve expansion.
|
|
Other Effectiveness Outcome - Valve Implant Acute Procedural Success
Tijdsspanne: Immediately Post-Valve Implant Procedure
|
To meet the definition of success, all the parameters listed below must be achieved, as assessed by Sites using direct pressure measurements and/or transesophageal echo (TEE):
|
Immediately Post-Valve Implant Procedure
|
|
Other Effectiveness Outcome - Pulmonary Regurgitation Grade
Tijdsspanne: Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
|
Pulmonary regurgitation grade categorized as none, trivial, mild, moderate, severe as evaluated by the Echo Core Laboratory. |
Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
|
|
Other Effectiveness Outcome - Pulmonary Stenosis Grade
Tijdsspanne: Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
|
Pulmonary stenosis grade categorized as none/trivial, mild, moderate, severe, as evaluated by the Echo Core Laboratory. |
Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
|
|
Other Effectiveness Outcome - Right Ventricular Measures
Tijdsspanne: Baseline, 30 days, 6 months, and annually through 5 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
|
Right ventricular (RV) measures, including RV dimension and strain will be evaluated by the Echo Core Laboratory. |
Baseline, 30 days, 6 months, and annually through 5 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
|
|
Other Effectiveness Outcome - Left Ventricular Measures
Tijdsspanne: Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
|
Left ventricular (LV) measures, including LV ejection fraction and strain will be evaluated by the Echo Core Laboratory. |
Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
|
|
Other Effectiveness Outcome - Modified Ross Functional Classification
Tijdsspanne: Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
|
Modified Ross Functional Class as assessed by the Site Investigators |
Baseline, 30 days, 6 months, and annually through 10 years post-valve implant and 30 days, 6 months, and 12 months post-valve expansion.
|
|
Other Effectiveness Outcome - PedsQL - Cardiac Module
Tijdsspanne: Baseline, 6 months and annually through 10 years post-valve implantation. Subjects that undergo post-implant valve expansion will be evaluated pre-valve expansion, and at 6 and 12 months post-valve expansion.
|
The Pediatric Qualify of Life Inventory (PedsQL) Cardiac Module will be administered by Site Personnel. |
Baseline, 6 months and annually through 10 years post-valve implantation. Subjects that undergo post-implant valve expansion will be evaluated pre-valve expansion, and at 6 and 12 months post-valve expansion.
|
|
Other Post-Implant Valve Expansion Safety Outcome - Composite
Tijdsspanne: 30 days after each post-implant valve expansion procedure
|
Composite Endpoint: Freedom from device-related complication through 30 days post-valve expansion as adjudicated by an independent CEC:
|
30 days after each post-implant valve expansion procedure
|
|
Other Post-Implant Valve Expansion Effectiveness Outcome - Acute Procedural Success
Tijdsspanne: Immediately after each post-implant valve expansion procedure
|
To meet the definition of success, at least one of the parameters listed below must be achieved after each post-implant valve expansion is performed, assessed during the same catheterization procedure:
|
Immediately after each post-implant valve expansion procedure
|
|
Other Post-Implant Valve Expansion Effectiveness Outcome - Hemodynamic Performance
Tijdsspanne: 6 months after each post-implant valve expansion procedure
|
Clinically acceptable hemodynamic performance at 6 months post-valve expansion procedure, as assessed by the Echo Core Laboratory via TTE, defined as:
|
6 months after each post-implant valve expansion procedure
|
Medewerkers en onderzoekers
Sponsor
Publicaties en nuttige links
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Werkelijk)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- AUT-CP-001
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .